Arkolith/Insider Trading/XLO/Form 4

Gilead Sciences, Inc.

10% OwnerXilio Therapeutics, Inc. (XLO) · full profile →Form 4 · filed Dec 1, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
0 non-derivative · 2 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Nov 26, 2025Option exercise(X)13.3M—$00
Nov 26, 2025Option exercise(X)13.3M$0.75$10.0M36.6M

Transaction Codes

X
Exercise of in-the-money derivative

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001123292-25-000675) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML